Diagnosing Glioblastoma and AML with D-2-Hydroxyglutarate Test
Diagnosis and monitoring of IDH1/IDH2/IDH3 dependent diseases such as: Glioblastomas, astrocytoma, oligodendrogliomas, oligoastrocytoma, acute myeloid leukaemia (AML), chondrosarcoma, intrahepatic cholangiocarcinoma, angioimmunoblastic T cell lymphoma. The technolgy describes a patented test, which is a simple and robust enzymatic assay with a readout in 3 hours. The test is suitable for 96-/384-well format, less expensive/time-consuming and high-throughput possible in opposite to established GC-MS test.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
